Related Experiment Video
Updated: Feb 9, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Immunotherapy: a glimmer of hope for metastatic prostate cancer
1Department of Internal Medicine, St. Vincent Hospital, Worcester, MA, USA. vishaljindal87@gmail.com.
Abstract:
Prostate cancer was the first cancer in which immunotherapy vaccine was approved by FDA in 2010 named Sipuleucel-T. No new immunotherapies have been approved since, as phase 3 trials didn't show any improvement in overall survival (OS) especially with immune checkpoint inhibitors. Currently tremendous amount of research is going on, in studying microenvironment of prostate cancer, finding new targets and biomarkers, and trying different combination therapies. Some of the new targets explored are VISTA and PARP inhibitors. Combination therapies have shown promising results in early phase trials and likely in near future we will have an effective immunotherapy for advanced prostate cancer. In this article we will review the current data and future of immunotherapy in prostate cancer.
Insights
Prostate cancer immunotherapy has seen limited success since Sipuleucel-T. Ongoing research into new targets and combination therapies shows promise for future effective treatments for advanced prostate cancer.
Area of Science:
- Oncology
- Immunology
Background:
- Prostate cancer was the first cancer with an approved immunotherapy vaccine (Sipuleucel-T) in 2010.
- Subsequent immunotherapies, including immune checkpoint inhibitors, have not demonstrated significant improvements in overall survival in phase 3 trials.
Purpose of the Study:
- To review the current landscape of immunotherapy for prostate cancer.
- To discuss emerging research, novel targets, and combination therapies for advanced prostate cancer.
Main Methods:
- Review of current scientific literature and clinical trial data on prostate cancer immunotherapy.
- Exploration of novel therapeutic targets such as VISTA and PARP inhibitors.
- Analysis of preliminary results from combination therapy trials.
Main Results:
- Limited success of approved immunotherapies in improving overall survival for prostate cancer.
- Promising early-phase results for novel targets and combination therapies.
- Active research focus on understanding the prostate cancer microenvironment.
Conclusions:
- Despite past challenges, significant research is underway to develop effective immunotherapies for prostate cancer.
- Combination therapies and targeting novel pathways like VISTA and PARP inhibitors represent a promising future direction.
- Effective immunotherapy for advanced prostate cancer may be achievable in the near future.
Related Concept Videos
Tumor Immunotherapy
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

